AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30870159 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline with identical volume and rate changes)
Number of subjects: 478
Study 30870159 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 478
Study 30870159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 478
Study 28877558 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher social status (leaders)
Number of subjects: 60
Study 28877558 — intervention group
Group type: COMPARATOR
Intervention: Lower social status (followers)
Number of subjects: 60
Study 25795741 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician care (additional intervention by a physician arriving by helicopter)
Number of subjects: 375
Study 25795741 — intervention group
Group type: COMPARATOR
Intervention: Standard ground paramedic treatment
Number of subjects: 375
Study 24012890 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-year healthy lifestyle intervention
Number of subjects: 600
Study 24012890 — intervention group
Group type: COMPARATOR
Intervention: 3-year school readiness program
Number of subjects: 600
Study 21429816 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Number of subjects: 23
Study 21429816 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 23
Study 19549748 — intervention group
Group type: EXPERIMENTAL
Intervention: GH reintroduction
Number of subjects: 12
Study 19549748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 17827951 — intervention group
Group type: EXPERIMENTAL
Intervention: rifaximin
Number of subjects: 58
Study 17827951 — intervention group
Group type: EXPERIMENTAL
Intervention: mesalazine
Number of subjects: 58
Study 15090392 — intervention group
Group type: EXPERIMENTAL
Intervention: Active low-energy extracorporeal shock wave treatment given weekly for 3 weeks
Number of subjects: 78
Study 15090392 — intervention group
Group type: COMPARATOR
Intervention: Placebo extracorporeal shock wave treatment (sham)
Number of subjects: 78
Study 16050432 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning bright light exposure (> or = 2500 lux in gaze direction) for 1 hour (09:30-10:30) Monday through Friday for 10 weeks
Number of subjects: 46
Study 16050432 — intervention group
Group type: COMPARATOR
Intervention: Usual indoor light (150-200 lux)
Number of subjects: 46
Study 10325829 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% nitrous oxide
Number of subjects: 9
Study 10325829 — intervention group
Group type: COMPARATOR
Intervention: 20% nitrogen gas mixture
Number of subjects: 9
Study 9772598 — intervention group
Group type: EXPERIMENTAL
Intervention: Lappaconitine compound (12 mg lappaconitine and 22.5 mg bupivacaine)
Number of subjects: 120
Study 9772598 — intervention group
Group type: COMPARATOR
Intervention: Morphine (2 mg)
Number of subjects: 120
Study 9772598 — intervention group
Group type: COMPARATOR
Intervention: Lappaconitine (12 mg) and bupivacaine (22.5 mg)
Number of subjects: 120
Study 1926895 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led education
Number of subjects: 25
Study 1926895 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher-led education
Number of subjects: 25
Study 1926895 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 25
Study 6416059 — intervention group
Group type: EXPERIMENTAL
Intervention: Paregoric
Number of subjects: 31
Study 6416059 — intervention group
Group type: COMPARATOR
Intervention: Phenobarbital
Number of subjects: 31
Study 30723735 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nutraceuticals containing 5 mg monacolin K, 200 mg Citrus bergamia, 400 mg Omega‐3, and 10 mcg trivalent chromium
Number of subjects: 50
Study 30723735 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nutraceuticals containing 3 mg monacolin K, 200 mg red yeast rice, 500 mg Berberine, 0.5 mg Astaxanthin, 200 mcg folic acid, 2 mg Coenzyme Q10, and 10 mg Policosanol
Number of subjects: 50
Study 28963804 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous telepractice care
Number of subjects: 82
Study 28963804 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 82
Study 26281163 — intervention group
Group type: EXPERIMENTAL
Intervention: De-Nol (bismuth subcitrate)
Number of subjects: 40
Study 26281163 — intervention group
Group type: EXPERIMENTAL
Intervention: Novobismol
Number of subjects: 40
Study 25294299 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice concentrate
Number of subjects: 24
Study 25294299 — intervention group
Group type: COMPARATOR
Intervention: Blackcurrant juice (control)
Number of subjects: 24
Study 22801191 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradetrusor onabotulinumtoxinA injections (300 IU)
Number of subjects: 32
Study 22801191 — intervention group
Group type: COMPARATOR
Intervention: Suburothelial onabotulinumtoxinA injections (300 IU)
Number of subjects: 32
Study 19241108 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (low dose)
Number of subjects: 1598
Study 19241108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1598
Study 19241108 — intervention group
Group type: COMPARATOR
Intervention: No tablets
Number of subjects: 1598
Study 17428299 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNTA 225 U
Number of subjects: 495
Study 17428299 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNTA 150 U
Number of subjects: 495
Study 17428299 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNTA 75 U
Number of subjects: 495
Study 17428299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 495
Study 14989807 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day mifepristone-misoprostol interval
Number of subjects: 200
Study 14989807 — intervention group
Group type: COMPARATOR
Intervention: 2-day mifepristone-misoprostol interval
Number of subjects: 200
Study 12536709 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency
Number of subjects: 310
Study 12536709 — intervention group
Group type: COMPARATOR
Intervention: Nd:YAG laser
Number of subjects: 310
Study 9849032 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia trachomatis antibodies
Number of subjects: 121
Study 9849032 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 121
Study 9849032 — intervention group
Group type: EXPERIMENTAL
Intervention: N. gonorrhoeae antibodies
Number of subjects: 121
Study 9156955 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg, once daily)
Number of subjects: 234
Study 9156955 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine SR (20 mg, twice daily)
Number of subjects: 234
Study 29354933 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) combined with Chinese herbal formula and letrozole
Number of subjects: 120
Study 29354933 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal formula and letrozole
Number of subjects: 120
Study 29354933 — intervention group
Group type: COMPARATOR
Intervention: Letrozole alone
Number of subjects: 120
Study 28552655 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic pelvic plexus ablation
Number of subjects: 102
Study 28552655 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic uterine artery occlusion and partial adenomyomectomy (control)
Number of subjects: 102
Study 28552655 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative time
Number of subjects: 102
Study 26283529 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced nutrition health care standards (intervention group)
Number of subjects: 960
Study 26283529 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 960
Study 23043154 — intervention group
Group type: EXPERIMENTAL
Intervention: Continence promotion interventions (3 experimental interventions)
Number of subjects: 667
Study 23043154 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 667
Study 21401409 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 63
Study 21401409 — intervention group
Group type: COMPARATOR
Intervention: Traditional surgical technique
Number of subjects: 63
Study 18665761 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) 20 min a day with a 5‐mW soft laser for 6 months
Number of subjects: 20
Study 18665761 — intervention group
Group type: COMPARATOR
Intervention: Betahistine 16 mg twice a day for 6 months
Number of subjects: 20
Study 16494539 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic splenectomy
Number of subjects: 28
Study 16494539 — intervention group
Group type: COMPARATOR
Intervention: Open splenectomy
Number of subjects: 28
Study 14609899 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo care (KC) for 30 minutes before and during heel-lancing procedure
Number of subjects: 74
Study 14609899 — intervention group
Group type: COMPARATOR
Intervention: Prone position in the isolette (control condition)
Number of subjects: 74
Study 10833331 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 244
Study 10833331 — intervention group
Group type: COMPARATOR
Intervention: CBS gene polymorphisms 699C ‐‐> T and 1080T ‐‐> C
Number of subjects: 244
Study 9438012 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunochemotherapy
Number of subjects: 0
Study 9438012 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 8441234 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF-I, 60 micrograms/kg, subcutaneous injections, administered at 0800, 1400, and 2000 hours for 5.5 days
Number of subjects: 8
Study 8441234 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-volume expanded and saline loaded subjects without rhIGF-I)
Number of subjects: 8
Study 2428593 — intervention group
Group type: EXPERIMENTAL
Intervention: WORD task
Number of subjects: 10
Study 2428593 — intervention group
Group type: EXPERIMENTAL
Intervention: CASE/WORD task
Number of subjects: 10
Study 2428593 — intervention group
Group type: EXPERIMENTAL
Intervention: Degraded stimuli
Number of subjects: 10
Study 2428593 — intervention group
Group type: EXPERIMENTAL
Intervention: WORD and CASE tasks
Number of subjects: 10
Study 28870129 — intervention group
Group type: EXPERIMENTAL
Intervention: Volar plating (surgical treatment)
Number of subjects: 97
Study 28870129 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (casting)
Number of subjects: 97
Study 26962133 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 3445
Study 26962133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3445
Study 25741871 — intervention group
Group type: EXPERIMENTAL
Intervention: PictureRx illustrated medication list
Number of subjects: 200
Study 25741871 — intervention group
Group type: COMPARATOR
Intervention: Usual care (written list of medications in preferred language, with indication but no images)
Number of subjects: 200
Study 22237419 — intervention group
Group type: EXPERIMENTAL
Intervention: sifilcon A penetrated hydrogel lenses (Dk/t ± 117) worn on a daily basis for 9 months
Number of subjects: 21
Study 22237419 — intervention group
Group type: COMPARATOR
Intervention: Control group (11 non-lens wearers)
Number of subjects: 21
Study 20837741 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular two-implant overdenture (OD)
Number of subjects: 20
Study 20837741 — intervention group
Group type: COMPARATOR
Intervention: Complete dentures (CD)
Number of subjects: 20
Study 18498682 — intervention group
Group type: EXPERIMENTAL
Intervention: Chunghyul-dan 600 mg a day
Number of subjects: 148
Study 18498682 — intervention group
Group type: COMPARATOR
Intervention: Antiplatelet agents
Number of subjects: 148
Study 16279156 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 3
Study 11952269 — intervention group
Group type: EXPERIMENTAL
Intervention: Helical pitch 1.0
Number of subjects: 60
Study 11952269 — intervention group
Group type: EXPERIMENTAL
Intervention: Helical pitch 1.3
Number of subjects: 60
Study 11952269 — intervention group
Group type: EXPERIMENTAL
Intervention: Helical pitch 1.5
Number of subjects: 60
Study 10081854 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral resection plus 100 mg. epirubicin
Number of subjects: 200
Study 10081854 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral resection plus 50 million units interferon-alpha2b
Number of subjects: 200
Study 10081854 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection only
Number of subjects: 200
Study 7498868 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 to 120 mg of hypericum extract bid
Number of subjects: 97
Study 7498868 — intervention group
Group type: EXPERIMENTAL
Intervention: hypericum extract
Number of subjects: 97
Study 2206813 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime (intramuscular)
Number of subjects: 466
Study 2206813 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin (oral)
Number of subjects: 466
Study 7002569 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg/day by mouth, in three divided doses
Number of subjects: 20
Study 7002569 — intervention group
Group type: COMPARATOR
Intervention: Placebo (weight‐ and disease‐matched)
Number of subjects: 20
Study 31066232 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium tanshinone IIA sulfonate (STS) 80 mg qd for 7 days
Number of subjects: 101
Study 31066232 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 101
Study 31066232 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium tanshinone IIA sulfonate (STS)
Number of subjects: 101
Study 30214156 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine 1-10 mg twice daily for up to 12 days
Number of subjects: 0
Study 30214156 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine 2.5-10 mg twice daily for up to 8 weeks
Number of subjects: 0
Study 27810972 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) - 2 doses (1 g/kg/dose)
Number of subjects: 308
Study 27810972 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 308
Study 27810972 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 308
Study 24630936 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit affective associations with fruits
Number of subjects: 107
Study 24630936 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit measures of affective associations
Number of subjects: 107
Study 22290978 — intervention group
Group type: EXPERIMENTAL
Intervention: Asunaprevir (200 to 600 mg twice daily)
Number of subjects: 0
Study 22290978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20814282 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone plus mepivacaine
Number of subjects: 45
Study 17221340 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg subcutaneous sumatriptan
Number of subjects: 43
Study 16250190 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented exercise therapy time as Arm BASIS training (n=20)
Number of subjects: 62
Study 16250190 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented exercise therapy time as Bobath therapy (n=20)
Number of subjects: 62
Study 16250190 — intervention group
Group type: COMPARATOR
Intervention: No augmented exercise therapy time (n=20)
Number of subjects: 62
Study 16250190 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented exercise therapy time as Arm BASIS training
Number of subjects: 62
Study 16250190 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented exercise therapy time as Bobath therapy
Number of subjects: 62
Study 11872999 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) + lamivudine (3TC) + indinavir (IDV)
Number of subjects: 279
Study 11872999 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) + lamivudine (3TC)
Number of subjects: 279
Study 11872999 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) + indinavir (IDV)
Number of subjects: 279
Study 11872999 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-drug regimen (ZDV + 3TC + IDV)
Number of subjects: 279
Study 11872999 — intervention group
Group type: COMPARATOR
Intervention: Less intensive regimens (ZDV + 3TC or ZDV + IDV)
Number of subjects: 279
Study 11872999 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinitiating either the original triple-drug regimen or a new combination of nucleoside analogue reverse transcriptase inhibitors and protease inhibitors
Number of subjects: 279
Study 10467900 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg of haloperidol
Number of subjects: 0
Study 10467900 — intervention group
Group type: EXPERIMENTAL
Intervention: 11 mg of midazolam
Number of subjects: 0
Study 10467900 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of scopolamine
Number of subjects: 0
Study 10467900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7834398 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 micrograms/kg rCD4‐IgG twice per week and 300 mg ZDV per day
Number of subjects: 41
Study 7834398 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 micrograms/kg rCD4‐IgG twice per week and 600 mg ZDV per day
Number of subjects: 41
Study 7834398 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 micrograms/kg rCD4‐IgG twice per week and 300 mg ZDV per day
Number of subjects: 41
Study 7834398 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 micrograms/kg rCD4‐IgG twice per week and 600 mg ZDV per day
Number of subjects: 41
Study 7834398 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,000 micrograms/kg rCD4‐IgG twice per week and 300 mg ZDV per day
Number of subjects: 41
Study 7834398 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV)
Number of subjects: 41
Study 7834398 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 41
Study 1964662 — intervention group
Group type: EXPERIMENTAL
Intervention: CY 216 (0.3 ml subcutaneous injections equivalent to 7,500 anti-Xa units)
Number of subjects: 4498
Study 1964662 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.3 ml saline solution)
Number of subjects: 4498
Study 6155131 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine 60 mg
Number of subjects: 18
Study 6155131 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine 120 mg
Number of subjects: 18
Study 6155131 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine 180 mg
Number of subjects: 18
Study 6155131 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine 15 mg
Number of subjects: 18
Study 6155131 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine 30 mg
Number of subjects: 18
Study 6155131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31958446 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 125 mg orally on day 1 and then 80 mg orally on days 2 to 7 with physician's choice of antitussive
Number of subjects: 128
Study 31958446 — intervention group
Group type: COMPARATOR
Intervention: Physician's choice of antitussive alone
Number of subjects: 128
Study 29484635 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipeptidyl Peptidase 1 Inhibitor AZD7986
Number of subjects: 0
Study 29484635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26465781 — intervention group
Group type: EXPERIMENTAL
Intervention: OCTREE (intraportal chemotherapy plus mFOLFOX6)
Number of subjects: 237
Study 26465781 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX6 (standard adjuvant chemotherapy)
Number of subjects: 237
Study 23743626 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 2
Study 23743626 — intervention group
Group type: COMPARATOR
Intervention: Distraction condition
Number of subjects: 2
Study 23743626 — intervention group
Group type: COMPARATOR
Intervention: Accuracy motivation condition
Number of subjects: 2
Study 23743626 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial width-to-height ratio (FWHR)
Number of subjects: 2
Study 23743626 — intervention group
Group type: EXPERIMENTAL
Intervention: Attractiveness
Number of subjects: 2
Study 23743626 — intervention group
Group type: EXPERIMENTAL
Intervention: Masculinity
Number of subjects: 2
Study 22533501 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Patient Simulator (HPS) practice
Number of subjects: 85
Study 22533501 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HPS practice)
Number of subjects: 85
Study 20557366 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day quadruple therapy (Omeprazole 20 mg, Amoxicillin 1.0 g, Clarithromycin 500 mg, Bismuth Potassium Citrate 220 mg, twice a day)
Number of subjects: 160
Study 20557366 — intervention group
Group type: COMPARATOR
Intervention: 7-day quadruple therapy (Omeprazole 20 mg, Amoxicillin 1.0 g, Clarithromycin 500 mg, Bismuth Potassium Citrate 220 mg, twice a day)
Number of subjects: 160
Study 18447631 — intervention group
Group type: EXPERIMENTAL
Intervention: GoChi (120 mL/day)
Number of subjects: 34
Study 18447631 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 34
Study 16414904 — intervention group
Group type: EXPERIMENTAL
Intervention: Non thermal dual wavelength light source (405-420 nm and 850-900 nm)
Number of subjects: 60
Study 16414904 — intervention group
Group type: COMPARATOR
Intervention: Glycolic peeling and daily appliance of vitamin C
Number of subjects: 60
Study 16414904 — intervention group
Group type: COMPARATOR
Intervention: Untreated by the light source
Number of subjects: 60
Study 16414904 — intervention group
Group type: COMPARATOR
Intervention: Untreated by the light source or treated by the light source on one side only
Number of subjects: 60
Study 12878618 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.08 micro g kg(‐1) min(‐1)
Number of subjects: 18
Study 12878618 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 18
Study 10762640 — intervention group
Group type: EXPERIMENTAL
Intervention: 5'‐DFUR (460 mg/m2/day, daily, for two years)
Number of subjects: 485
Study 10762640 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU (115 mg/m2/day, daily, for two years)
Number of subjects: 485
Study 9467249 — intervention group
Group type: EXPERIMENTAL
Intervention: HBA1 concentration
Number of subjects: 37
Study 9467249 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting blood glucose concentration
Number of subjects: 37